West Pharma Q4 adj EPS flat YoY at $1.83; FY24 adj EPS guidance $7.50-$7.75 vs $8.08 in FY23

WEST PHARMACEUTICAL SERVICES INC

2023-FY EPS reported $7.88 revenue$2,949,800,000

Q4 net sales $732.0M (+3.3% YoY); full-year net sales $2.950B (+2.2% YoY).
Q4 reported EPS $1.83 (+34.6% YoY); full-year reported EPS $7.88 (+1.9% YoY).
FY24 guidance: net sales $3.000B-$3.025B; adjusted EPS $7.50-$7.75; organic sales growth ~2%-3%.
Proprietary Products organic sales down 0.3% Q4; COVID headwinds cited; excluding COVID, high-single-digit growth.
FY23 free cash flow $414.5M (down 5.7%); repurchased 1.27M shares for $438.3M at avg $346.34.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

WEST PHARMACEUTICAL SERVICES INC reported Full-year 2024 results: revenue in a range of $3.000 billion to $3.025 billion, EPS adjusted-diluted EPS in a range of $7.50 to $7.75. Guidance initiated.

Period: Full-year 2024
Revenue: in a range of $3.000 billion to $3.025 billion
EPS: adjusted-diluted EPS in a range of $7.50 to $7.75
Guidance: initiated
Result: preliminary results

Exact text from the filing

The Company is introducing full-year 2024 financial guidance of net sales in a range of $3.000 billion to $3.025 billion and adjusted-diluted EPS in a range of $7.50 to $7.75.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

WEST PHARMACEUTICAL SERVICES INC reported the fourth-quarter and full-year 2023 results: revenue $2.950 billion, EPS $7.88. Guidance reaffirmed.

Period: the fourth-quarter and full-year 2023
Revenue: $2.950 billion
EPS: $7.88
Guidance: reaffirmed
Result: reported results

Exact text from the filing

full-year 2023 and introduced full-year 2024 financial guidance. Fourth-Quarter and Full-Year 2023 Summary (comparisons to prior-year period) • Fourth-quarter 2023 net sales of $732.0 million grew 3.3%; organic net sales growth was 1.4%. Full-year 2023 net sales of $2.950 billion grew 2.2%; organic net sales growth was 1.6%. • Fourth-quarter 2023 reported-diluted EPS

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

WEST PHARMACEUTICAL SERVICES INC reported the fourth-quarter and full-year 2023 results: revenue $2.950 billion, EPS $7.88. Guidance reaffirmed.

Period: the fourth-quarter and full-year 2023
Revenue: $2.950 billion
EPS: $7.88
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Full-year 2023 net sales of $2.950 billion grew 2.2%; organic net sales growth was 1.6%.

View on SEC.gov

171 earnings releases filed in the last 30 days. Browse all earnings releases →

WEST PHARMACEUTICAL SERVICES INC filing history →

Source: SEC EDGAR

accession 0000105770-24-000009

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.